| ||
Oxford
I-CBP112
SGC Oxford Info
About SGC Oxford
Bromosporine (BSP)
Oxford News Slideshow Page
Epigenetics Conference 2013
Oxford Symposium on Rare Diseases 2013: 'Protein misfolding and aggregation'
Pfizer and SGC Oxford receive the first Wellcome Trust Pathfinder Award for Rare Diseases
The Pfizer-SGC project aims to tackle a rare, hereditary metabolic disorder called homocystinuria, which leaves patients unable to metabolise the amino acid methionine.
Regulating Symbiotic Bacteria in Your Body
Professor Matthew R. Redinbo
Department of Chemistry, University of North Carolina
Richard Doll Building
Thursday 6th September 2012
An epigenetic mechanism to inhibit inflammation
Researchers from Oxford University, GlaxoSmithKline, Cellzome, and Memorial Sloan Kettering Hospital have developed and characterised the first selective inhibitor for a specific class of histone demethylases